Join us this March for the first ever CURE Patient-Focused Sessions, taking place at the Miami Breast Cancer Conference! 

×
To start your customized experience click the start button
Customize ?  
Start
Cancer Types
Quick Links
Award Programs
About Us
Careers
Contact Us
Newsroom
Privacy Policy
Terms & Conditions
 
Twitter
Face Book
YouTube
Instagram
 
 
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2018
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.

Kidney Cancer

Feature Video
Cabometyx (cabozantinib) was granted approval by the Food and Drug Administration (FDA) for previously untreated patients who have advanced renal cell carcinoma (RCC).
Jason M. Broderick
Frontline Opdivo (nivolumab) plus Yervoy (ipilimumab) was granted a priority review to a supplemental biologics license application (sBLA) to be used to treat patients with intermediate- and poor-risk patients with advanced renal cell carcinoma (RCC).
The FDA approved Sutent to be used in patients who had a nephrectomy and are at high risk of their kidney cancer returning.
Gina Columbus

Sumanta Kumar Pal, M.D., associate professor, Department of Medical Oncology, City of Hope, covered the scope of exciting genitourinary cancer data presented at the 2017 ESMO Congress, with a sharp focus on the CABOSUN and CheckMate-214 trials.
CHRISTIN MELTON, ELS
The latest drugs for advanced kidney cancer are stirring optimism.
Jason Harris
The Food and Drug Administration approved the first ever biosimilar to treat a variety of cancers.
 
Danielle Bucco
In an interview with CURE, Badani, a professor of Urology at Mount Sinai Hospital, discusses the benefits of robotic surgery in RCC. 
 
Jason Harris

Cabometyx had better progression-free survival rates than Sutent (sunitinib) for certain patients with renal cell carcinoma. 

Jason Harris
Progression-free survival (PFS) was not significantly improved with the combination of dalantercept plus Inlyta (axitinib) in patients with advanced renal cell carcinoma (RCC) compared with placebo, according to the results from the phase 2 DART trial.
Jason M. Broderick
Bavencio and Inlyta together produced a promising response for some patients with renal cell carcinoma. 
×
×

Sign In

Not a member? Sign up now!
Continue without login
Continue
×

Sign Up

Patient Caregiver Advocate Other